A new rapid-response study designed and led by the Duke Clinical Research Institute (DCRI) seeks to engage healthcare workers across the nation to understand the impact of COVID-19 on their health and to evaluate whether hydroxychloroquine can prevent COVID-19 infections in healthcare workers at high risk of contracting this novel coronavirus. Read more…
BGI Genomics and its US subsidiary BGI Americas announced the FDA has issued an Emergency Use Authorization (EUA) for its RT-PCR kit for detecting SARS-CoV-2. Read more…
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19. Read more…
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Hydroxychloroquine sulphate (Plaquenil) an analog of chloroquine has an established track record for treating malaria and has demonstrated in vitro activity against the SARS-CoV and therefore being considered as possible treatment for COVID-19. Read more…